⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL767523 | 0.91 | — | — | |
| SCHEMBL767568 | 0.90 | TDP1 (0.30) | — | |
| SCHEMBL767774 | 0.88 | NPC1 (0.33) | — | |
| SCHEMBL767567 | 0.84 | HRH3 (0.33) | — | |
| SCHEMBL767695 | 0.83 | — | — | |
| SCHEMBL767668 | 0.81 | — | — | |
| SCHEMBL767677 | 0.81 | PIM1 (0.31) | — | |
| SCHEMBL767644 | 0.81 | SIGMAR1 (0.30) | — | |
| SCHEMBL767673 | 0.79 | HSD11B1 (0.32) | — | |
| SCHEMBL767698 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160348110-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-9453043-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-07-30 | — | — | US | disclosed |
| US-8975389-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |